Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

Here is Dr. Punam Krishan's expert health advice... This video can not be played. To play this video you need to enable ...

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

“Broken skin barriers” are real. They’re the subject of great interest from " skinfluencers " on TikTok, but they’re also ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Bristol Myers Squibb Co. forecast 2025 sales and profit below Wall Street’s expectations — a sign that declining sales of ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor letter. A copy of the investor letter can be downloaded here. U.S. equities ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get ...

Discover my personal experience with NanoDefense Pro reviews and how it transformed my nail health in just 30 days.

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...